The efficacy and safety of tirzepatide, with a special focus on cardiovascular safety, were investigated in the 52-week SURPASS-4 trial testing tirzepatide versus insulin glargine in adults with T2D and a high cardiovascular risk under inadequate glycemic control at baseline on one to three oral glucose-lowering medications (metformin, sulfonylurea, SGLT-2 inhibitor) (74)
When blood pressure drops, less blood and oxygen may reach the brain, leading to feelings of lightheadedness or dizziness
Hughes, S., & Neumiller, J
Intramuscular: These injections are more common, as they tend to have better results
(It is not as scary or as challenging as it may seem at first)
They serve as an adjunct tool to support continued appetite control and metabolic health in the long term